Emerging treatments
Pirfenidone
Pirfenidone, an anti-inflammatory and anti-fibrotic agent, has been shown to slow down disease progression in idiopathic pulmonary fibrosis. A single, non-randomised clinical trial of pirfenidone in patients with asbestosis showed a limited benefit.[36]
Use of this content is subject to our disclaimer